CoChat

FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis

Open access
Mandrioli, Jessica, Amedei, Amedeo, Cammarota, Giovanni, Niccolai, Elena, Zucchi, Elisabetta, D'Amico, Roberto, Ricci, Federica, Quaranta, Gianluca, Spanu, Teresa, Masucci, Luca · 2019 · Frontiers in Neurology
Cited by 78

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background and rationale: Among the key players in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS), microglia and T regulatory lymphocytes (Treg) are candidate cells for modifying the course of the disease. The gut microbiota (GM) acts by shaping immune tolerance and regulating the Treg number and suppressive function, besides circulating neuropeptides and other immune cells that play in concert through the gut-brain axis. Previous mouse models have shown an altered enteric flora in early stage ALS, pointing to a possible GM role in ALS pathogenesis. Fecal Microbial Transplantation (FMT) is a well-known therapeutic intervention used to re-establish the proper microenvironment and to modulate enteric and systemic immunity. Methods: We are going to perform a multicenter randomized double-blind clinical trial employing FMT as a therapeutic intervention for ALS patients (NCT0376632). 42 ALS patients, at an early stage, will be enrolled with a 2:1 allocation ratio (28 FMT-treated patients versus 14 controls). Study duration will be 12 months per patient. Three endoscopic procedures for intestinal biopsies in FMT and control groups are predicted at baseline, month 6 and month 12; at baseline and at month 6 fresh feces from healthy donors will be infused at patients in the intervention arm. The primary outcome is a significant change in Treg number between FMT-treated patients and control arm from baseline to month 6. Secondary outcomes include specific biological aims, involving in-depth analysis of immune cells and inflammatory status changes, central and peripheral biomarkers of ALS, besides comprehensive analysis of the gut, saliva and fecal microbiota. Other secondary aims include validated clinical outcomes of ALS (survival, forced vital capacity, and modifications in ALSFRS-R), besides safety and quality of life. Expected results: We await FMT to increase Treg number and suppressive functionality, switching the immune system surrounding motorneurons to an anti-inflammatory, neuroprotective status. Extensive analysis on immune cell populations, cytokines levels, and microbiota (gut, fecal and saliva) will shed light on early processes possibly leading the degenerative ALS course. Conclusions: This is the first trial with FMT as a potential intervention to modify immunological response to ALS and disease progression at an early stage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2019.01021

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 31

  1. Oskarsson, 2018, Amyotrophic lateral sclerosis: an update for 2018, Mayo Clin Proc., 93, 1617, 10.1016/j.mayocp.2018.04.007 · DOI · Paper page
  2. Rossi, 2016, Old versus new mechanisms in the pathogenesis of ALS, Brain Pathol., 26, 276, 10.1111/bpa.12355 · DOI
  3. Geloso, 2017, The dual role of microglia in ALS: mechanisms and therapeutic approaches, Front Aging Neurosci., 9, 242, 10.3389/fnagi.2017.00242 · DOI · Paper page
  4. Tiemessen, 2007, CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages, PNAS., 104, 19446, 10.1073/pnas.0706832104 · DOI · Paper page
  5. Liu, 2011, Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice, Immunol Cell Biol., 89, 130, 10.1038/icb.2010.70 · DOI · Paper page
  6. Schetters, 2018, Neuroinflammation: microglia and T cells get ready to tango, Front Immunol., 8, 1905, 10.3389/fimmu.2017.01905 · DOI · Paper page
  7. Beers, 2011, Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis, Brain., 134, 1293, 10.1093/brain/awr074 · DOI · Paper page
  8. Henkel, 2013, Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival, EMBO Mol Med., 5, 64, 10.1002/emmm.201201544 · DOI · Paper page
  9. Thonhoff, 2018, Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study, Neurol Neuroimmunol Neuroinflamm., 5, e465, 10.1212/NXI.0000000000000465 · DOI · Paper page
  10. Backhed, 2005, Host-bacterial mutualism in the human intestine, Science., 307, 1915, 10.1126/science.1104816 · DOI · Paper page
  11. Conway, 1997, Development of intestinal microbiota, 3, 10.1007/978-1-4757-0322-1_1 · DOI
  12. Eckburg, 2005, Diversity of the human intestinal microbial flora, Science., 308, 1635, 10.1126/science.1110591 · DOI · Paper page
  13. Sabel, 2003, Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death, Am J Epidemiol., 157, 898, 10.1093/aje/kwg090 · DOI · Paper page
  14. Khanna, 2018, Microbiota replacement therapies: innovation in gastrointestinal care, Clin Pharmacol Ther., 103, 102, 10.1002/cpt.923 · DOI · Paper page
  15. Kimura, 2006, Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS, Neurology., 66, 265, 10.1212/01.wnl.0000194316.91908.8a · DOI · Paper page
  16. Mantovani, 2009, Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process, J Neuroimmunol., 210, 73, 10.1016/j.jneuroim.2009.02.012 · DOI · Paper page
  17. Baxter, 2016, Adverse events in faecal microbiota transplant: a review of the literature, J Hosp Infect., 92, 117, 10.1016/j.jhin.2015.10.024 · DOI · Paper page
  18. Wang, 2016, Systematic review: adverse events of fecal microbiota transplantation, PLoS ONE., 11, e0161174, 10.1371/journal.pone.0161174 · DOI · Paper page
  19. Brandt, 2015, Fecal microbiota transplant: respice, adspice, prospice, J Clin Gastroenterol., 49, 65, 10.1097/MCG.0000000000000346 · DOI
  20. Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery., 44, 854
  21. Schwan, 1983, Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces, Lancet., 2, 845, 10.1016/S0140-6736(83)90753-5 · DOI · Paper page
  22. Cammarota, 2015, Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs, . Aliment Pharmacol Ther., 41, 835, 10.1111/apt.13144 · DOI · Paper page
  23. Fang, 2016, Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis, Int J Neurosci., 126, 771, 10.3109/00207454.2015.1096271 · DOI · Paper page
  24. Scheperjans, 2016, Can microbiota research change our understanding of neurodegenerative diseases?, Neurodegener Dis Manage, 6, 81, 10.2217/nmt-2015-0012 · DOI
  25. Kuraszkiewicz, 2018, Are there modifiable environmental factors related to amyotrophic lateral sclerosis?, Front Neurol, 9, 220, 10.3389/fneur.2018.00220 · DOI
  26. Tremlett, 2016, Gut microbiota composition and relapse risk in pediatric MS: a pilot study, J Neurol Sci., 363, 153, 10.1016/j.jns.2016.02.042 · DOI · Paper page
  27. Kadowaki, 2016, Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3, Nat Commun., 7, 11639, 10.1038/ncomms11639 · DOI · Paper page
  28. Fang, 2016, Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing, Front Microbiol., 7, 1479, 10.3389/fmicb.2016.01479 · DOI · Paper page
  29. Mazzini, 2018, Potential role of gut microbiota in ALS pathogenesis and possible novel therapeutic strategies, J Clin Gastroenterol., 52, S68, 10.1097/MCG.0000000000001042 · DOI · Paper page
  30. Piccione, 2015, Autonomic system and amyotrophic lateral sclerosis, Muscle Nerve., 51, 676, 10.1002/mus.24457 · DOI
  31. Pecere, 2015, Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection, Aliment Pharmacol Ther., 42, 1030, 10.1111/apt.13362 · DOI

Cited by

See all 78

Metadata

Authors
Mandrioli, J., Amedei, A., Cammarota, G., Niccolai, E., Zucchi, E., D'Amico, R., Ricci, F., Quaranta, G., Spanu, T., & Masucci, L.
Venue
Frontiers in Neurology
Published
2019-09-20
Volume
10
Pages
1021-1021
ISSN
1664-2295 (ISSN-L)
OpenAlex
W2973416631
Cited by
78
References
32
FWCI
2.51
Type
journal article
Language
en
Open access
gold
Funders
Agenzia Italiana del Farmaco, Ministero della Salute (RF-2016-02361616)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. https://app.cochat.ai/papers/10.3389/fneur.2019.01021
The paper
Mandrioli, J., Amedei, A., Cammarota, G., Niccolai, E., Zucchi, E., D'Amico, R., Ricci, F., Quaranta, G., Spanu, T., & Masucci, L. (2019). FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.01021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.